Recent research on the use of very high dose JAKis in patients with a genetic immune deficiency with gain of function affecting the JAK-STAT pathway, and accompanied by autoimmune, lymphoproliferative and/or infectious complications, did not reveal any VTE, thus raising the question of the intrinsic risk of VTE linked to inflammatory diseases, irrespective of JAKi and dose treatment [48]. This evidence concerns the gene SOAT1 and Immunodeficiency.